Anti-PKR (phospho T451) antibody [EPR2152Y]
- RabMAb
- Recombinant
- What is this?
1
(1 Review)
|
(33 Publications)
Rabbit Recombinant Monoclonal PKR phospho T451 antibody. Suitable for Dot, WB and reacts with Pig, Human samples. Cited in 33 publications.
View Alternative Names
PKR, PRKR, EIF2AK2, Eukaryotic translation initiation factor 2-alpha kinase 2, Interferon-inducible RNA-dependent protein kinase, P1/eIF-2A protein kinase, Protein kinase RNA-activated, Tyrosine-protein kinase EIF2AK2, p68 kinase, eIF-2A protein kinase 2, Protein kinase R
- WB
Supplier Data
Western blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (AB81303)
Purified format.
Blocking buffer : 5% NFDM/TBST
Diluting buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (ab81303) at 1/2000 dilution
Lane 1:
Untreated HeLa (human cervix adenocarcinoma) whole cell lysate at 10 µg
Lane 2:
HeLa (human cervix adenocarcinoma) treated with Interferon-α and Calyculin A whole cell lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 62 kDa
false
- WB
Lab
Western blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (AB81303)
Blocking/Diluting Buffer and concentration : 5% NFDM /TBST
All lanes:
Western blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (ab81303) at 0.048 µg/mL
Lane 1:
HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2:
HeLa treated with 1000U/ml IFN α1 for 18 hours and then treated with 100nM Calyculin A for 15 minutes whole cell lysate at 20 µg
Lane 3:
HeLa treated with 1000U/ml IFN α1 for 18 hours and then treated with 100nM Calyculin A for 15 minutes whole cell lysate. Then the membrane was incubated with alkaline phosphatase. at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 0.01 µg/mL
Predicted band size: 62 kDa
false
- WB
Unknown
Western blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (AB81303)
All lanes:
Western blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (ab81303) at 1/2000 dilution
Lane 1:
HeLa cell lysate un-treated at 10 µg
Lane 2:
HeLa cell lysate treated with IFN-alpha at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 62 kDa
Observed band size: 68 kDa
false
- Dot
Unknown
Dot Blot - Anti-PKR (phospho T451) antibody [EPR2152Y] (AB81303)
Dot blot analysis of PKR (pT451) phospho peptide (Lane 1), PKR non-phospho peptide (Lane 2), labeling PKR (phospho T451) with ab81303 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/100000.
Blocking and dilution buffer : 5% NFDM/TBST.
Exposure time : 3 minutes
Related conjugates and formulations (1)
-
Anti-PKR (phospho T451) antibody [EPR2152Y] - BSA and Azide free
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (33)
Recent publications for all applications. Explore the full list and refine your search
JCI insight 10: PubMed40626357
2025
Applications
Unspecified application
Species
Unspecified reactive species
Communications biology 8:589 PubMed40205031
2025
Applications
Unspecified application
Species
Unspecified reactive species
Molecular cell 84:2935-2948.e7 PubMed39019044
2024
Applications
Unspecified application
Species
Unspecified reactive species
PLoS pathogens 20:e1012355 PubMed38935808
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal for immunotherapy of cancer 11: PubMed37935565
2023
Applications
Unspecified application
Species
Unspecified reactive species
PLoS pathogens 19:e1011443 PubMed37327222
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed36555509
2022
Applications
Unspecified application
Species
Unspecified reactive species
Communications biology 5:822 PubMed35970927
2022
Applications
Unspecified application
Species
Unspecified reactive species
Veterinary research 52:148 PubMed34930429
2021
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 50:1201-1220 PubMed34671803
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com